Comments
Loading...

ANI Pharmaceuticals Analyst Ratings

ANIPNASDAQ
Logo brought to you by Benzinga Data
$64.22
-0.13-0.20%
At close: -
$64.22
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$94.00
Lowest Price Target1
$62.00
Consensus Price Target1
$79.75

ANI Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ANIP | Benzinga

ANI Pharmaceuticals Inc has a consensus price target of $79.75 based on the ratings of 9 analysts. The high is $94 issued by HC Wainwright & Co. on March 17, 2025. The low is $62 issued by Truist Securities on October 22, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Jefferies, and JP Morgan on March 17, 2025, March 14, 2025, and March 12, 2025, respectively. With an average price target of $86.33 between HC Wainwright & Co., Jefferies, and JP Morgan, there's an implied 34.43% upside for ANI Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Oct 24
1
Nov 24
1
Dec 24
5
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Jefferies
JP Morgan
Guggenheim
Leerink Partners

1calculated from analyst ratings

Analyst Ratings for ANI Pharmaceuticals

Buy NowGet Alert
03/17/2025Buy Now46.37%HC Wainwright & Co.
Oren Livnat
$94 → $94ReiteratesBuy → BuyGet Alert
03/14/2025Buy Now24.57%Jefferies
Glen Santangelo
→ $80Initiates → BuyGet Alert
03/12/2025Buy Now32.36%JP Morgan
Ekaterina Knyazkova
→ $85Initiates → OverweightGet Alert
03/05/2025Buy Now33.91%Guggenheim
Vamil Divan
$84 → $86MaintainsBuyGet Alert
03/03/2025Buy Now46.37%HC Wainwright & Co.
Oren Livnat
$94 → $94ReiteratesBuy → BuyGet Alert
12/11/2024Buy Now24.57%Leerink Partners
Faisal Khurshid
→ $80Initiates → OutperformGet Alert
11/11/2024Buy Now46.37%HC Wainwright & Co.
Oren Livnat
$94 → $94ReiteratesBuy → BuyGet Alert
10/22/2024Buy Now-3.46%Truist Securities
Gregory Fraser
$60 → $62MaintainsHoldGet Alert
10/11/2024Buy Now5.89%Piper Sandler
David Amsellem
→ $68Initiates → OverweightGet Alert
09/18/2024Buy Now29.24%Raymond James
Elliot Wilbur
$81 → $83MaintainsOutperformGet Alert
09/17/2024Buy Now46.37%HC Wainwright & Co.
Oren Livnat
$94 → $94ReiteratesBuy → BuyGet Alert
09/11/2024Buy Now-6.57%Truist Securities
Gregory Fraser
$80 → $60DowngradeBuy → HoldGet Alert
08/07/2024Buy Now46.37%HC Wainwright & Co.
Oren Livnat
$94 → $94ReiteratesBuy → BuyGet Alert
06/26/2024Buy Now46.37%HC Wainwright & Co.
Oren Livnat
$87 → $94MaintainsBuyGet Alert
05/13/2024Buy Now35.47%HC Wainwright & Co.
Oren Livnat
$83 → $87MaintainsBuyGet Alert
04/23/2024Buy Now19.9%Guggenheim
Vamil Divan
$77 → $77ReiteratesBuy → BuyGet Alert
03/15/2024Buy NowCapital One
Timothy Chiang
Initiates → OverweightGet Alert
03/05/2024Buy Now19.9%Guggenheim
Vamil Divan
$70 → $77MaintainsBuyGet Alert
03/04/2024Buy Now29.24%HC Wainwright & Co.
Oren Livnat
$73 → $83MaintainsBuyGet Alert
03/01/2024Buy Now24.57%Truist Securities
Gregory Fraser
$72 → $80MaintainsBuyGet Alert
02/16/2024Buy Now12.11%Truist Securities
Gregory Fraser
$70 → $72MaintainsBuyGet Alert
10/19/2023Buy Now12.11%Guggenheim
Vamil Divan
→ $72ReiteratesBuy → BuyGet Alert
09/13/2023Buy Now12.11%Guggenheim
Vamil Divan
→ $72ReiteratesBuy → BuyGet Alert
08/22/2023Buy Now13.67%HC Wainwright & Co.
Oren Livnat
$60 → $73MaintainsBuyGet Alert
08/21/2023Buy Now9%Truist Securities
Gregory Fraser
→ $70ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now12.11%Guggenheim
Vamil Divan
$62 → $72MaintainsBuyGet Alert
07/27/2023Buy Now-3.46%Guggenheim
Vamil Divan
$59 → $62MaintainsBuyGet Alert
07/21/2023Buy Now-6.57%Truist Securities
Gregory Fraser
$52 → $60MaintainsBuyGet Alert
05/09/2023Buy Now-8.13%Guggenheim
Vamil Divan
$55 → $59MaintainsBuyGet Alert
05/09/2023Buy Now-19.03%Truist Securities
Gregory Fraser
$50 → $52MaintainsBuyGet Alert
05/09/2023Buy Now-23.7%Raymond James
Elliot Wilbur
$48 → $49MaintainsOutperformGet Alert
05/09/2023Buy Now-6.57%HC Wainwright & Co.
Oren Livnat
$53 → $60MaintainsBuyGet Alert
03/13/2023Buy Now-17.47%HC Wainwright & Co.
Oren Livnat
$50 → $53MaintainsBuyGet Alert
03/01/2023Buy Now-14.36%Guggenheim
Vamil Divan
→ $55Initiates → BuyGet Alert
02/21/2023Buy Now-22.14%HC Wainwright & Co.
Oren Livnat
→ $50Reiterates → BuyGet Alert
09/07/2022Buy Now-22.14%HC Wainwright & Co.
Oren Livnat
→ $50Initiates → BuyGet Alert
08/09/2022Buy Now-25.26%Raymond James
Elliot Wilbur
$47 → $48MaintainsOutperformGet Alert

FAQ

Q

What is the target price for ANI Pharmaceuticals (ANIP) stock?

A

The latest price target for ANI Pharmaceuticals (NASDAQ:ANIP) was reported by HC Wainwright & Co. on March 17, 2025. The analyst firm set a price target for $94.00 expecting ANIP to rise to within 12 months (a possible 46.37% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ANI Pharmaceuticals (ANIP)?

A

The latest analyst rating for ANI Pharmaceuticals (NASDAQ:ANIP) was provided by HC Wainwright & Co., and ANI Pharmaceuticals reiterated their buy rating.

Q

When was the last upgrade for ANI Pharmaceuticals (ANIP)?

A

There is no last upgrade for ANI Pharmaceuticals

Q

When was the last downgrade for ANI Pharmaceuticals (ANIP)?

A

The last downgrade for ANI Pharmaceuticals Inc happened on September 11, 2024 when Truist Securities changed their price target from $80 to $60 for ANI Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for ANI Pharmaceuticals (ANIP)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ANI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ANI Pharmaceuticals was filed on March 17, 2025 so you should expect the next rating to be made available sometime around March 17, 2026.

Q

Is the Analyst Rating ANI Pharmaceuticals (ANIP) correct?

A

While ratings are subjective and will change, the latest ANI Pharmaceuticals (ANIP) rating was a reiterated with a price target of $94.00 to $94.00. The current price ANI Pharmaceuticals (ANIP) is trading at is $64.22, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch